hENT1 Predicts Benefit from Gemcitabine in Pancreatic Cancer but Only with Low CDA mRNA
Karen Aughton(University of Liverpool), William Greenhalf(University of Liverpool), Julia Mayerle(LMU Klinikum), David Goldstein(New South Wales Department of Health), Richard Jackson(University of Liverpool), Paula Ghaneh(University of Liverpool), Daniel H. Palmer(University of Liverpool), Andrew Scarfe(Cancer Institute (WIA)), John R. Mackey(University of Alberta), Markus W. Büchler(Heidelberg University), Nils Elander(University of Liverpool), Ross Carter(Glasgow Royal Infirmary), John P. Neoptolemos(University of Liverpool), A.G. Evans(Princeton University), David Cunningham(Royal Marsden NHS Foundation Trust), Bengt Glimelius(Uppsala University), Richard Charnley(Newcastle upon Tyne Hospitals NHS Foundation Trust), Juan W. Valle(Cancer Research UK Manchester Institute), Niall C. Tebbutt(Austin Health), Alan Anthoney(St James's University Hospital), Christopher Halloran(University of Liverpool), Markus M. Lerch(Ludwig-Maximilians-Universität München), Fiona Campbell(University of Birmingham), Thilo Hackert(Universität Hamburg), Jennifer Shannon(The University of Sydney), Eithne Costello(University of Liverpool)
Cited by 14
Related Papers
Cisplatin plus Gemcitabine versus Gemcitabine for Biliary Tract Cancer
|New England Journal of Medicine|2010|4.5k
Erlotinib Plus Gemcitabine Compared With Gemcitabine Alone in Patients With Advanced Pancreatic Cancer: A Phase III Trial of the National Cancer Institute of Canada Clinical Trials Group
|Journal of Clinical Oncology|2007|3.9k
<i>K-ras</i> Mutations and Benefit from Cetuximab in Advanced Colorectal Cancer
|New England Journal of Medicine|2008|3.6k
Assessment of Liver Function in Patients With Hepatocellular Carcinoma: A New Evidence-Based Approach—The ALBI Grade
|Journal of Clinical Oncology|2014|2.8k